Free Trial
LON:SN

Smith & Nephew (SN) Share Price, News & Analysis

Smith & Nephew logo
GBX 974.80 -13.40 (-1.36%)
(As of 11/20/2024 ET)

About Smith & Nephew Stock (LON:SN)

Key Stats

Today's Range
971.51
987.40
50-Day Range
917.60
1,202
52-Week Range
N/A
Volume
1.55 million shs
Average Volume
343,671 shs
Market Capitalization
£8.50 billion
P/E Ratio
3,610.37
Dividend Yield
2.97%
Price Target
GBX 3,956.20
Consensus Rating
Moderate Buy

Company Overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
73rd Percentile Overall Score

SN MarketRank™: 

Smith & Nephew scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Smith & Nephew has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Smith & Nephew has received no research coverage in the past 90 days.

  • Read more about Smith & Nephew's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Smith & Nephew is 3,610.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 126.99.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Smith & Nephew is 3,610.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 93.09.

  • Price to Earnings Growth Ratio

    Smith & Nephew has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Smith & Nephew has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SN.
  • Dividend Yield

    Smith & Nephew pays a meaningful dividend of 2.59%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Smith & Nephew does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Smith & Nephew is 10,740.74%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Smith & Nephew's dividend.
  • Short Interest

    There is no current short interest data available for SN.
  • News Sentiment

    Smith & Nephew has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Smith & Nephew this week, compared to 2 articles on an average week.
  • Search Interest

    Only 12 people have searched for SN on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Smith & Nephew to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Smith & Nephew insiders have bought more of their company's stock than they have sold. Specifically, they have bought £50,019.84 in company stock and sold GBX 0 in company stock.

  • Percentage Held by Insiders

    Only 0.19% of the stock of Smith & Nephew is held by insiders.

  • Percentage Held by Institutions

    62.24% of the stock of Smith & Nephew is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Smith & Nephew's insider trading history.
Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SN Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Barclays Remains a Hold on Smith & Nephew (SN)
Smith & Nephew (SN) Receives a Buy from Jefferies
Smith & Nephew (SN) Gets a Buy from RBC Capital
See More Headlines

SN Stock Analysis - Frequently Asked Questions

Smith & Nephew's stock was trading at GBX 1,078.50 at the beginning of the year. Since then, SN stock has decreased by 9.6% and is now trading at GBX 974.80.
View the best growth stocks for 2024 here
.

Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Barclays (BARC), Lloyds Banking Group (LLOY), GSK (GSK), AstraZeneca (AZN) and Meta Platforms (META).

Company Calendar

Ex-Dividend for 11/8 Dividend
10/03/2024
Dividend Payable
11/08/2024
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Consumer Goods
CIK
N/A
Fax
N/A
Employees
18,452
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 3,956.20
High Stock Price Target
£145
Low Stock Price Target
GBX 1,150
Potential Upside/Downside
+305.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
£305 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£5.64 billion
Cash Flow
GBX 52.17 per share
Book Value
GBX 596 per share

Miscellaneous

Free Float
N/A
Market Cap
£8.50 billion
Optionable
Not Optionable
Beta
0.62
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (LON:SN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners